TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 29376112
Drug: IVIG+ (Intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: IVIG+ (Intravenous immunoglobulin with prednisone and risk-adapted chemotherapy)
Study: 29376112
Drug: NO-IVIG (No
Approvals — FDA: no, EMA: no, PMDA: no
Description: NO-IVIG (No intravenous immunoglobulin with prednisone and risk-adapted chemotherapy)
Study: 27250658
Drug: Sedation with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sedation with a daily wake-up attempt
Study: 22206777
Drug: 1 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg/kg reslizumab
Study: 22206777
Drug: 2 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg/kg reslizumab
Study: 22206777
Drug: 3 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg/kg reslizumab
Study: 24980988
Drug: Etanercept 50
Normalized name: etanercept 50 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etanercept 50 mg BIW
Study: 15948997
Drug: Etanercept 25
Normalized name: etanercept 25 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etanercept 25 mg BIW (after dose reduction from 50 mg)
Study: 15948997
Drug: Etanercept 25
Normalized name: etanercept 25 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etanercept 25 mg BIW (continuous)
Study: 15948997
Drug: Placebo followed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo followed by etanercept 25 mg BIW
Study: 8902255
Drug: Cyclandelate (1,200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclandelate (1,200 mg daily for 12 weeks)
Study: 8902255
Drug: Propranolol (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (120 mg daily for 12 weeks)
Study: 27460541
Drug: Ezetimibe 10
Normalized name: ezetimibe 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ezetimibe 10 mg/day for 12 weeks
Study: 20370923
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of surgery and trocar techniques (Group B)
Study: 17711710
Drug: Intravenous tirofiban
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous tirofiban bolus (10 microg/kg) prior to coronary angiography (Group IV)
Study: 17711710
Drug: Intravenous tirofiban
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous tirofiban (Group IV)
Study: 11432685
Drug: Ipsapirone (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ipsapirone (0.3 mg/kg)
Study: 1334515
Drug: Zileuton (5-lipoxygenase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zileuton (5-lipoxygenase inhibitor)
Study: 2165088
Drug: Clonidine (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonidine (75 micrograms twice daily)
Study: 2165088
Drug: Clonidine plus
Normalized name: Clonidine
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clonidine plus chlorthalidone (15 mg)
Study: 2165088
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus chlorthalidone (15 mg)
Study: 91439
Drug: Five-drug combination
Normalized name: fivehorn smotherweed pollen extract
DrugBank: Bassia hyssopifolia pollen (DB10941)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Five-drug combination chemotherapy program containing cis-dichlorodiammineplatinum(II)
Study: 31421669
Drug: Individualized, tablet-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individualized, tablet-based physiotherapy training programme
Study: 16751033
Drug: 2 hours
Normalized name: PATCH, TRANSDERMAL 72 HOURS
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 hours of daily patching with 1 hour of near visual activities
Study: 15289492
Drug: PC-SPES (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: PC-SPES (3 capsules orally three times a day)
Study: 15289492
Drug: Diethylstilbestrol (DES,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diethylstilbestrol (DES, 3 mg orally once a day)
Study: 12451007
Drug: 500 mL
Normalized name: TPN Bag 500 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mL of mineral water
Study: 9720812
Drug: Immunotherapy against
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunotherapy against birch pollen
Study: 17241499
Drug: Intravenous dexmedetomidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous dexmedetomidine infusion
Study: 25137430
Drug: Physiologic saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physiologic saline infusion
Study: 15515877
Drug: Low-dose insulin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose insulin regimen (1 IU/h)
Study: 11527675
Drug: Glutamine supplementation
Normalized name: Glutamine
DrugBank: L-Glutamine (DB00130)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glutamine supplementation (30 g/d)
Study: 9764549
Drug: Erythromycin estolate
Normalized name: Erythromycin Estolate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythromycin estolate at 40 mg/kg/day in two divided doses
Study: 9764549
Drug: Amoxicillin at
Normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amoxicillin at 50 mg/kg/day in two divided doses
Study: 31801404
Drug: Broadband light
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Broadband light (BBL) treatment
Study: 23786776
Drug: Tamoxifen 10
Normalized name: tamoxifen 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen 10 mg/week
Study: 11587974
Drug: Conservative Treatment
Normalized name: Conserved dopamine neurotrophic factor
DrugBank: HER-902 (DB17948)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative Treatment (CT) - sleep hygiene and weight loss
Study: 2791799
Drug: Mealtime regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mealtime regimen (400 mg three times a day with meals)
Study: 2791799
Drug: Bedtime regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bedtime regimen (1200 mg at bedtime)
Study: 2791799
Drug: Reference regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference regimen (200 mg three times a day with meals and 600 mg at bedtime)
Study: 338025
Drug: Co-trimoxazole (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Co-trimoxazole (10 ml by intravenous infusion)
Study: 31635844
Drug: Indirect Pulp
Normalized name: acai fruit pulp
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indirect Pulp Therapy (IPT)
Study: 27250495
Drug: Marginally low
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Marginally low Se-B (40-59 μg/l)
Study: 27250495
Drug: Optimal Se-B
Normalized name: Selenomethionine Se-75
DrugBank: Selenomethionine Se-75 (DB09400)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimal Se-B (≥80 μg/l)
Study: 27250495
Drug: Suboptimal Se-B
Normalized name: Selenomethionine Se-75
DrugBank: Selenomethionine Se-75 (DB09400)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suboptimal Se-B (60-79 μg/l)
Study: 19321587
Drug: 80 mg/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg/d of isoflavones
Study: 19321587
Drug: 120 mg/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 120 mg/d of isoflavones
Study: 9750706
Drug: Methylprednisolone (M)
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylprednisolone (M) 30 mg.kg‐1 over 1 hour, followed by 5.4 mg.kg‐1.h‐1 for 23 hours
Study: 9750706
Drug: Nimodipine (N)
Normalized name: Nimodipine
DrugBank: Nimodipine (DB00393)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nimodipine (N) 0.015 mg.kg‐1.h‐1 over 2 hours followed by 0.03 mg.kg‐1.h‐1 for 7 days
Study: 9750706
Drug: No medical
Approvals — FDA: no, EMA: no, PMDA: no
Description: No medical treatment (P)
Study: 31099632
Drug: Experimental arm
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Experimental arm (new anticancer drugs)
Study: 23820061
Drug: Control arm
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control arm (standard treatment)
Study: 27914033
Drug: L-carnitine 2
Normalized name: L-Carnitine 250mg Oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-carnitine 2 g/day plus simvastatin 20 mg/day
Study: 27914033
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus simvastatin 20 mg/day
Study: 21354368
Drug: Pramipexole (0.125-0.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pramipexole (0.125-0.75 mg/d)
Study: 18500518
Drug: Imatinib 400
Normalized name: imatinib 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imatinib 400 mg p.o. with 20 mL antacid (1.6 g Al(OH)(3) + 1.6 g Mg(OH)(2)) 15 min before imatinib
Study: 17413095
Drug: Normal calcium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal calcium intake (1 g/d) during weight loss
Study: 17413095
Drug: High calcium
Normalized name: Nutritional Supplement Oral Liquid [ENSURE HIGH CALCIUM]
Approvals — FDA: no, EMA: no, PMDA: no
Description: High calcium intake (1.8 g/d) during weight loss
Study: 17413095
Drug: Weight maintenance
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weight maintenance group (1 g Ca/d)
Study: 12577419
Drug: Astragalus injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Astragalus injection (ASI) 20 ml in 500 ml 5% glucose solution, once a day for 2 months
Study: 9701408
Drug: SR 48968
Normalized name: SR 121463
DrugBank: SR 121463 (DB05455)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SR 48968 (100 mg)
Study: 31897483
Drug: Multinutrient supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multinutrient supplementation (14 g l-arginine, 14 g l-glutamine, 1250 mg vitamin C, 55 mg zinc daily for 14 days before and after surgery)
Study: 24595577
Drug: Existing DNA
Normalized name: Toxoplasma gondii DNA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Existing DNA repair and antioxidant and growth factor topical products with SPF 50 sunscreens
Study: 10190764
Drug: Oramorph SR
Normalized name: Oramorph SR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oramorph SR 30 mg
Study: 7436160
Drug: Aerosol metaproterenol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aerosol metaproterenol (5 puffs, 0.65 mg each, total 3.25 mg)
Study: 7436160
Drug: Combined regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined regimen (oral metaproterenol 20 mg + aerosol metaproterenol)
Study: 7436160
Drug: Oral metaproterenol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral metaproterenol (20 mg tablet)
Study: 23749293
Drug: BG-12 (dimethyl
Approvals — FDA: no, EMA: no, PMDA: no
Description: BG-12 (dimethyl fumarate) three times daily (TID)
Study: 9767368
Drug: Digoxin 0.25
Normalized name: digoxin 0.25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Digoxin 0.25 mg twice daily for 10 days
Study: 9767368
Drug: Digitoxin 0.1
Normalized name: digitoxin 0.1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Digitoxin 0.1 mg daily for 10 days
Study: 8121439
Drug: Hormonal factors
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormonal factors (oral contraceptives and high parity)
Study: 3113804
Drug: Cefuroxime axetil
Normalized name: Cefuroxime Axetil
DrugBank: Cefuroxime (DB01112)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefuroxime axetil (125 mg, twice daily)
Study: 3113804
Drug: Phenoxymethyl penicillin
Normalized name: Phenoxymethyl Penicillin
DrugBank: Phenoxymethylpenicillin (DB00417)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Phenoxymethyl penicillin (250 mg, three times daily)
Study: 26603245
Drug: Hydration group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydration group (n=17) coached to increase water intake by up to 1.5 L/day for 6 weeks
Study: 1784882
Drug: Intravenous regional
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous regional administration of methylprednisolone (40 mg)
Study: 26845030
Drug: Interpersonal psychotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interpersonal psychotherapy (IPT) plus treatment as usual (TAU)
Study: 21696894
Drug: Disulfiram (0,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Disulfiram (0, 250, and 500 mg/d, p.o.)
Study: 21696894
Drug: Ethanol (0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethanol (0.4 g/kg i.v.)
Study: 21696894
Drug: Disulfiram (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Disulfiram (500 mg/d, p.o.)
Study: 10778866
Drug: Tyrosine intake
Normalized name: Tyrosine
DrugBank: Tyrosine (DB00135)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tyrosine intake at varying levels (3.0, 4.5, 6.0, 7.5, 9.0, 10.5, and 12.0 mg x kg(‐1) x d(‐1))
Study: 7870903
Drug: Intravenous diazepam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous diazepam (logarithmically increasing doses at 15-min intervals)
Study: 30871768
Drug: Ulipristal acetate
Normalized name: Ulipristal Acetate
DrugBank: Ulipristal (DB08867)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Ulipristal acetate (UPA) treatment
Study: 20832282
Drug: PCEA+AMB (PCEA
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCEA+AMB (PCEA with AMB of 5 mL every hour)
Study: 20832282
Drug: PCEA+BI (PCEA
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCEA+BI (PCEA with basal continuous infusion of 5mL/h)
Study: 10828010
Drug: L-asparaginase during
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-asparaginase during consolidation therapy in the medium-risk group (MRG)
Study: 10828010
Drug: No L-asparaginase
Approvals — FDA: no, EMA: no, PMDA: no
Description: No L-asparaginase during consolidation therapy in the medium-risk group (MRG)
Study: 10828010
Drug: Overall treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall treatment regimen in ALL-BFM 90
Study: 10828010
Drug: Standard-risk group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-risk group (SRG) treatment regimen
Study: 10828010
Drug: Medium-risk group
Normalized name: Medium-Chain Triglycerides
DrugBank: Medium-chain triglycerides (DB13959)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medium-risk group (MRG) treatment regimen
Study: 10828010
Drug: High-risk group
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-risk group (HRG) treatment regimen
Study: 8651156
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg of meperidine
Study: 8651156
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg of midazolam
Study: 2000050
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment (clonidine plus hydralazine)
Study: 6406198
Drug: Intraperitoneal (i.p.)
Normalized name: Intraperitoneal Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraperitoneal (i.p.) insulin infusion
Study: 6406198
Drug: Subcutaneous (s.c.)
Normalized name: immune globulin subcutaneous (human) - klhw Injection [Xembify]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous (s.c.) insulin infusion
Study: 6406198
Drug: Intravenous (i.v.)
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (i.v.) insulin infusion
Study: 27044507
Drug: Standard ECLS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard ECLS therapy at normothermia
Study: 15303996
Drug: Weekly iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly iron supplements (108 mg iron) given for 10 weeks
Study: 15303996
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no iron supplements)
Study: 2104790
Drug: Omeprazole (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole (20 mg)
Study: 272044
Drug: Fluoride solution
Normalized name: Apatate with Fluoride Solution
DrugBank: Sodium fluorophosphate (DB09484)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoride solution application post-restoration
Study: 28661170
Drug: Tablet computer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet computer
Study: 23301240
Drug: Fluoridated toothpaste
Normalized name: sodium fluoride Toothpaste
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoridated toothpaste (Colgate Dental Cream)
Study: 19836169
Drug: Donepezil (5mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Donepezil (5mg daily for 3 days)
Study: 16417782
Drug: Osteoking (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Osteoking (25 ml every other day for 10 days)
Study: 16417782
Drug: Sanchi‐dansheng tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sanchi‐dansheng tablets (3 tablets thrice a day for 10 days)
Study: 16417782
Drug: Sanchi‐dansheng tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sanchi‐dansheng tablets
Study: 11575540
Drug: Ephedrine (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ephedrine (2 mg/min) plus phenylephrine (10 microg/min)
Study: 11575540
Drug: Ephedrine (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ephedrine (2 mg/min) alone
Study: 9663418
Drug: 3 x
Normalized name: Xenon (133 xe)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 x 100 mg alizapride plus placebo (group A)
Study: 9663418
Drug: 3 x
Normalized name: Xenon (133 xe)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 x 100 mg alizapride plus 3 x 4 mg dexamethasone (group B)
Study: 8176255
Drug: Topical 0.05%
Normalized name: ingenol topical 0.05% topical gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 0.05% betamethasone dipropionate applied at 1600 h for 2 or 6 hours
Study: 8176255
Drug: Topical 0.05%
Normalized name: ingenol topical 0.05% topical gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 0.05% betamethasone dipropionate
Study: 7486094
Drug: Morphine 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine 0.1 mg/kg IV
Study: 2285605
Drug: Anandron (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anandron (300 mg) + orchiectomy
Study: 20665554
Drug: Direct screening
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Direct screening (invitation by letter followed by a home visit to administer the GDS-15)
Study: 19644132
Drug: Daily oral
Normalized name: GEMTESA 75 MG Once-Daily Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily oral nutritional supplement containing 1.3 mg of riboflavin for 6 weeks
Study: 17442999
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy with vinorelbine and cisplatin
Study: 17442999
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy (vinorelbine and cisplatin)
Study: 26177937
Drug: Olodaterol 2.5
Normalized name: OLODATEROL 2.5MCG/ACTUAT 14D ORAL INHL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olodaterol 2.5 μg BID
Study: 25187881
Drug: Olodaterol 5
Normalized name: Olodaterol
DrugBank: Olodaterol (DB09080)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Olodaterol 5 μg QD
Study: 26177937
Drug: Olodaterol 5
Normalized name: Olodaterol
DrugBank: Olodaterol (DB09080)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Olodaterol 5 μg BID
Study: 25187881
Drug: Olodaterol 10
Normalized name: Olodaterol
DrugBank: Olodaterol (DB09080)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Olodaterol 10 μg QD
Study: 26177937
Drug: Olodaterol 5
Normalized name: Olodaterol
DrugBank: Olodaterol (DB09080)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Olodaterol 5 μg QD vs Olodaterol 2.5 μg BID
Study: 26177937
Drug: Olodaterol 10
Normalized name: Olodaterol
DrugBank: Olodaterol (DB09080)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Olodaterol 10 μg QD vs Olodaterol 5 μg BID
Study: 26382173
Drug: Aggressive medical
Normalized name: ZO SKIN HEALTH Aggressive Anti-Aging Program KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aggressive medical therapy alone
Study: 23500245
Drug: Aggressive medical
Normalized name: ZO SKIN HEALTH Aggressive Anti-Aging Program KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aggressive medical therapy with prompt revascularization
Study: 21690555
Drug: High-dose cytarabine
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose cytarabine (HDAraC)
Study: 21690555
Drug: Timed-sequential chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Timed-sequential chemotherapy (TSC)
Study: 8192452
Drug: Norfloxacin with
Normalized name: Norfloxacin
DrugBank: Norfloxacin (DB01059)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Norfloxacin with sucralfate (1 g)
Study: 8192452
Drug: Ofloxacin with
Normalized name: Ofloxacin
DrugBank: Ofloxacin (DB01165)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ofloxacin with sucralfate (1 g)
Study: 18566197
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (patient-controlled analgesia morphine)
Study: 15788122
Drug: Protein group
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protein group (30 g/d protein)
Study: 11954675
Drug: Experimental medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental medication
Study: 2215987
Drug: Propofol injection
Normalized name: propofol Injection
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol injection for induction of anesthesia
Study: 2215987
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of Diprivan (Propofol) for maintenance of anesthesia
Study: 31087325
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg of micronized vaginal progesterone once daily from 16-26 weeks until 36 weeks of gestation
Study: 31087325
Drug: Placebo once
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo once daily from 16-26 weeks until 36 weeks of gestation
Study: 31087325
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg of micronized vaginal progesterone once daily
Study: 27715351
Drug: Yeast β-glucan
Normalized name: yeast, beta-D-glucan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yeast β-glucan 477 mg/capsule
Study: 27056418
Drug: 7-day MAP
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7-day MAP treatment
Study: 27056418
Drug: 14-day MAP
Approvals — FDA: no, EMA: no, PMDA: no
Description: 14-day MAP treatment
Study: 24372492
Drug: Immediate long
Normalized name: long pepper extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate long license suspension
Study: 3898010
Drug: Theophylline (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Theophylline (10 mg/kg for 2-6 months, 12 mg/kg for 6-12 months, 16 mg/kg for 12-24 months)
Study: 29793828
Drug: Low-dose transdermal
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose transdermal testosterone gel (1.62%, 1.25 g)
Study: 29793828
Drug: Full replacement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full replacement dose testosterone gel (1.62%, 5 g)